



January 18, 2023  
JCR Pharmaceuticals Co., Ltd.

Translation

## **JCR Receives the European Award for Best Practices 2022 by the ESQR**

Jan. 18, 2023-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced that the European Society for Quality Research, ESQR, has bestowed its European Award for Best Practices 2022 to JCR.

The ESQR is a European organization, with Head Office in Switzerland, dedicated to quality improvement techniques recognition and research. The ESQR makes a positive contribution to quality culture through its annual conventions and award giving ceremonies in the major cities. It recognizes excellence disseminates innovation and visionary thinking, spreads knowledge, shares conformity assessment practices and facilitates networking. The European Award for Best Practices recognizes the organizations, companies, public administrations and individuals with the best practices and results in quality management strategies.

In our Midterm Business Plan for 2020-2022, "REVOLUTION", we positioned the "Qualitative and quantitative reorganization of the quality assurance system" as the top management priority. We established a new organization in charge of integrated quality control and constructed a new quality testing facility within our Kobe Science Park Center, which was completed in November 2022. We are continuously improving our production and quality assurance system to achieve an even more stable supply, and we believe that this award by the ESQR is a recognition of these ongoing efforts.

The European Award for Best Practices 2022 convention was held on December 11, 2022 in Brussels, Belgium. JCR was represented by Anne Bechet, General Manager of JCR Europe B.V., who accepted the trophy and gave the acceptance speech. A video of the ceremony is available on the [official ESQR website](#).

### **About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products

in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

### **Cautionary Statement Regarding Forward-Looking Statements**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

#### Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

###